Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 5Waldenstrom Macroglobulinemia 2Lymphoma, B-Cell, Marginal Zone 2Recurrence 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, B-Cell 1

Interventions

venetoclax 5Rituximab 4Cyclophosphamide 4Whole-Body Irradiation 3Cyclosporine 3zanubrutinib 2pirtobrutinib 2fludarabine phosphate 2fludarabine 2Prednisone 2Mycophenolic Acid 2Magnetic Resonance Spectroscopy 2Lenalidomide 2treosulfan 1pomalidomide 1obinutuzumab 1ibrutinib 1Vincristine 1Tacrolimus 1Stem Cell Transplantation 1Specimen Handling 1Sirolimus 1R-CHOP protocol 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Methotrexate 1Melphalan 1Maintenance 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × pirtobrutinib × 30 days × Clear all
NCT07231952 2026-06-03

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
40 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05734495 2026-05-28

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
46 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡